In the Media

Optimizing Phase IV Communications

Posted Friday, January 13, 2012

Sam BarnesChuck Johnston


  • IMG Optimizing Phase IV

    (Photo Credit: ©iStockphoto.com/nicolas_)

In an article published in Communiqué, a reference in healthcare communications and an essential resource for pharma professionnals, AXON Communications’ Chuck Johnston and Sam Barnes explain that developing and executing comprehensive study communications strategies around clinical trials are a critical element of pharma stakeholder engagement.

Clinical trials can usually fall into four distinct phases, each of which with a different goal and designed to answer a different question. Phase IV clinical trials are usually undertaken after a new drug has been approved for use by health and regulatory agencies.

Knowing that these Phase IV studies can represent a greater communications challenge, the authors explain how companies can effectively engage investigators and participating patients, as well as the range of stakeholders who need to understand and value the results.

Download


1  comment(s) for  Optimizing Phase IV Communications

Aimee Sulliman

Posted Tuesday, February 5, 2013

Terrific article - insightful and very relevant for manufacturers reflecting the focus on real world safety, HEOR, and overall evolution in the payer environment.

Flag Comment

  Comment

By submitting a comment, you agree to NATIONAL's Guidelines, Terms & Conditions, and Privacy Policy

Comments posted on the individual contributor's personal opinions, and do not necessarily represent the views of NATIONAL Public Relations, its companies, its vendors, or its clients, or the contributor's employers or clients. Send comments to:[email protected]